Skip to Main Content

Advertisement intended for health care professionals

Skip Nav Destination

Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma

Blood Adv (2021) 5 (15): 2935–2944.
Currently there are no citedby results. Try again later.
Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals